Atrial fibrillation and stroke prevention: brief observations on the last decade

References

• Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the european union, from 2000 to 2060. Eur Heart J 2013;34(35):2746-51
   PubMed Web of Science ®Google Scholar
• Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 2013;110(2):213-22
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 2012;33:1500-10
   PubMed Web of Science ®Google Scholar
• Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012;107(6):1053-65
   PubMed Web of Science ®Google Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013;99:1166-72
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis working group on thrombosis – Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109:569-79
   PubMed Web of Science ®Google Scholar
• De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the esc working group on thrombosis – task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-107
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289-304
   PubMed Web of Science ®Google Scholar
• Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013;34:1041-9
   PubMed Web of Science ®Google Scholar
• Lip GY. Recommendations for thromboprophylaxis in the 2012 focused update of the esc guidelines on atrial fibrillation: a commentary. J Thromb Haemost 2013;11:615-26
   PubMed Web of Science ®Google Scholar
• Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110(6):1189-98
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968-77
   PubMed Web of Science ®Google Scholar
• O’Neil WM, Welner SA, Lip GY. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? Thromb Haemost 2013;109:497-503
   PubMed Web of Science ®Google Scholar
• Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012;108(4):672-82
   PubMed Web of Science ®Google Scholar
• Diener HC. Pro: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.”. Thromb Haemost 2013;110:493-5
   PubMedGoogle Scholar
• Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47
   PubMed Web of Science ®Google Scholar
• Turpie AG, Kreutz R, Llau J, et al. Management consensus guidance for the use of rivaroxaban – an oral, direct factor xa inhibitor. Thromb Haemost 2012;108:876-86
   PubMed Web of Science ®Google Scholar
• Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among european patients with atrial fibrillation. A modelling analysis from the euro heart survey. Thromb Haemost 2013;109:328-36
   PubMed Web of Science ®Google Scholar
• Guo Y, Pisters R, Apostolakis S, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? Int J Cardiol 2013;168:515-22
   PubMedGoogle Scholar
• Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest 2010;138:1093-100
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell’Aniello S, Simon T, et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013;109:431-9
   PubMed Web of Science ®Google Scholar
• Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013;110:560-8
   PubMed Web of Science ®Google Scholar
• Friberg L, Rosenqvist M, Lip G. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012;125:2298-307
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9
   PubMed Web of Science ®Google Scholar
• Roldan V, Marin F, Manzano-Fernandez S, et al. The has-bled score has better prediction accuracy for major bleeding than the CHADS or CHADS-VASC scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013;62(23):2199-204
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Lane DA, Buller H, Lip GY. Comparison. of the CHADS2, CHA2DS2 -VASC and has-bled scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the amadeus trial. Thromb Haemost 2013;110(5):1074-9
   Google Scholar
• Azoulay L, Dell’aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the same-tt2r2 score. Chest 2013;144:1555-63
   PubMed Web of Science ®Google Scholar